Overview

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2028-09-29

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.

Phase:

PHASE1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Bevacizumab
enzalutamide
Fluorouracil
Leucovorin